Related references
Note: Only part of the references are listed.Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
Nikhil C. Munshi et al.
BLOOD (2011)
Guidelines for supportive care in multiple myeloma 2011
John A. Snowden et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)
Murielle Roussel et al.
BLOOD (2010)
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
Henk M. Lokhorst et al.
BLOOD (2010)
Renal function in newly diagnosed multiple myeloma - A demographic study of 1353 patients
Lene Meldgaard Knudsen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - A randomized study
Martin Hjorth et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations
Bilal Mohty et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Primary plasma cell leukemia and autologous stem cell transplantation
Mary B. Drake et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Efficacy and outcome of autologous transplantation in rare myelomas
Curly Morris et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
Jean-Luc Harousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
Maria-Victoria Mateos et al.
LANCET ONCOLOGY (2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
E. Terpos et al.
ANNALS OF ONCOLOGY (2009)
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
Heinz Ludwig et al.
BLOOD (2009)
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
Marcello Rotta et al.
BLOOD (2009)
Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients
Graham Peter Mead et al.
BLOOD (2009)
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
Prashant Kapoor et al.
BLOOD (2009)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Ola Landgren et al.
BLOOD (2009)
Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma
Sagar Lonial et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)
Jenny Bird et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
Owen A. O'Connor et al.
CLINICAL CANCER RESEARCH (2009)
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
Edward A. Stadtmauer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010
Hermann Brenner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
Cyrille Hulin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study
Meletios A. Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure
Andrew Spencer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
Ambuj Kumar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
M. A. Dimopoulos et al.
LEUKEMIA (2009)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R. Fonseca et al.
LEUKEMIA (2009)
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
C. B. Reeder et al.
LEUKEMIA (2009)
Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis
Shaji K. Kumar et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma
Tomer Mark et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
Laura Rosinol et al.
BLOOD (2008)
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
Angela Dispenzieri et al.
BLOOD (2008)
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo et al.
BLOOD (2008)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
The evolving use of serum free light chain assays in haematology
Guy Pratt
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy:: results of a Phase I clinical trial
Wolfram Poenisch et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
IgM myeloma:: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14)
Sylvia Feyler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
Pellegrino Musto et al.
CANCER (2008)
A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma
Lisa K. Hicks et al.
CANCER TREATMENT REVIEWS (2008)
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Andy C. Rawstron et al.
HAEMATOLOGICA (2008)
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression
Maria-Victoria Mateos et al.
HAEMATOLOGICA (2008)
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma
S. Vincent Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Individualizing treatment of patients with myeloma in the era of novel agents
Jesus San-Miguel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
Juan Jose Lahuerta et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
J. F. San-Miguel et al.
LEUKEMIA (2008)
Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens
Maria Roussou et al.
LEUKEMIA & LYMPHOMA (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo et al.
LEUKEMIA (2008)
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma
Ruben Niesvizky et al.
BLOOD (2008)
Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry
Samer Z. Al-Quran et al.
HUMAN PATHOLOGY (2007)
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis
Nionhang Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma:: final time-to-event results of the APEX trial
Paul G. Richardson et al.
BLOOD (2007)
Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study
Sylvia Feyler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Thierry Facon et al.
LANCET (2007)
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
Helgi J. K. van de Velde et al.
HAEMATOLOGICA (2007)
Phase II Pethema trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma:: Efficacy and clinical implications of tumor response kinetics
Laura Rosinol et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
Ernesto Perez-Persona et al.
BLOOD (2007)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:: A report from the GIMEMA -: Italian multiple myeloma network
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
Robert Z. Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
S. Kumar et al.
LEUKEMIA (2007)
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group
K. Zervas et al.
ANNALS OF ONCOLOGY (2007)
High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma
Don M. Benson et al.
LEUKEMIA RESEARCH (2007)
Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma
John Kuruvilla et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
An internadional field study of the reliability and validity of a disease-specfic questionnanire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
K. Cocks et al.
EUROPEAN JOURNAL OF CANCER (2007)
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
Robert A. Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
P. Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study
Michele Cavo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
George Mulligan et al.
BLOOD (2007)
Reduced-intensity conditioning for myeloma:: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning
Charles Crawley et al.
BLOOD (2007)
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents
Efstathios Kastritis et al.
HAEMATOLOGICA (2007)
Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus IV melphalan
J. Vela-Ojeda et al.
ANNALS OF HEMATOLOGY (2007)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy et al.
BLOOD (2007)
A comparison of allografting with autografting for newly diagnosed myeloma
Benedetto Bruno et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study
Asher A. Chanan-Khan et al.
BLOOD (2007)
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
A. K. Stewart et al.
LEUKEMIA (2007)
Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance
V. Eleutherakis-Papaiakovou et al.
LEUKEMIA & LYMPHOMA (2007)
A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7
Chaim Shustik et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Guidelines for the use of imaging in the management of myeloma
Shirley D'Sa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Autologous stem cell transplantation beyond 60 years of age
E. Jantunen
BONE MARROW TRANSPLANTATION (2006)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson et al.
BLOOD (2006)
Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma
Michel Attal et al.
BLOOD (2006)
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma
R. Fonseca et al.
LEUKEMIA (2006)
Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials
Mark Drayson et al.
BLOOD (2006)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study
Jennifer M. Bird et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Bortezomib is effective in primary plasma cell leukemia
Damian P. J. Finnegan et al.
LEUKEMIA & LYMPHOMA (2006)
Multiple myeloma in end-stage renal disease
Jeffrey G. Penfield
SEMINARS IN DIALYSIS (2006)
The role of anatomic and functional staging in myeloma: Description of Durie/Salmon PLUS staging system
Brian G. M. Durie
EUROPEAN JOURNAL OF CANCER (2006)
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
F Garban et al.
BLOOD (2006)
Short-course radiotherapy is not optimal for spinal cord compression due to myeloma
D Rades et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
A Palumbo et al.
LANCET (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
B Barlogie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Myeloma - new approaches to combined nephrological-haematological management
M Haubitz et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
A Glasmacher et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321
B Barlogie et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Guidelines on the diagnosis and management of multiple myeloma 2005
A Smith et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the eastern cooperative oncology group
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
High-dose idarubicin, busulphan and melphalan for autologous stem cell transplantation in multiple myeloma responsive to DAV chemotherapy: Comparison with a historical control
S Capria et al.
ACTA HAEMATOLOGICA (2006)
Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party
BM Augustson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
SV Rajkumar et al.
BLOOD (2005)
Plasma exchange when myeloma presents as acute renal failure - A randomized, controlled trial
WF Clark et al.
ANNALS OF INTERNAL MEDICINE (2005)
Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma
S Gerull et al.
BONE MARROW TRANSPLANTATION (2005)
Myeloma bone disease: pathophysiology and management
E Terpos et al.
ANNALS OF ONCOLOGY (2005)
Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure
LM Knudsen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
M Cavo et al.
BLOOD (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma
HE Oakervee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma
C Kyriakou et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
S Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma:: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT
C Crawley et al.
BLOOD (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Interferon-α as maintenance therapy in patients with multiple myeloma
CG Schaar et al.
ANNALS OF ONCOLOGY (2005)
Bortezornib in recurrent and/or refractory multiple myeloma - Initial clinical experience in patients with impaired renal function
S Jagannath et al.
CANCER (2005)
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma
P Tosi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Immunoglobulin M myeloma: Evaluation of molecular features and cytokine expression
K Konduri et al.
CLINICAL LYMPHOMA (2005)
Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure - a retrospective analysis and recommendations for dose adjustment
K Carlson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
IgD multiple myeloma - a clinical profile and outcome with chemotherapy and autologous stem cell transplantation
A Wechalekar et al.
ANNALS OF HEMATOLOGY (2005)
Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning - evidence for a superior outcome using melphalan combined with total body irradiation
HM Hunter et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Stem-cell transplantation in multiple myeloma
JL Harousseau et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2005)
Early response predicts thalidomide efficiency in patients with advanced multiple myeloma
A Waage et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant
CK Lee et al.
BONE MARROW TRANSPLANTATION (2004)
The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma
R García-Sanz et al.
LEUKEMIA (2004)
Podocyte injury associated glomerulopathies induced by pamidronate
YM Barri et al.
KIDNEY INTERNATIONAL (2004)
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure
P Tosi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2004)
Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease
G Srkalovic et al.
CANCER (2004)
Serum free light chains for monitoring multiple myeloma
GP Mead et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant
AK Stewart et al.
CLINICAL CANCER RESEARCH (2004)
Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation
M Mohty et al.
BONE MARROW TRANSPLANTATION (2004)
High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy
S Kumar et al.
BONE MARROW TRANSPLANTATION (2004)
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
A Palumbo et al.
BLOOD (2004)
Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma
N Kröger et al.
BLOOD (2004)
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma
HM Lokhorst et al.
BLOOD (2004)
Stem cell mobilization in multiple myeloma patients: Do we need an age-adjusted regimen for the elderly?
T Fietz et al.
JOURNAL OF CLINICAL APHERESIS (2004)
Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects
S D'Sa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Bisphosphonate treatment for multiple myeloma
E Terpos et al.
DRUGS OF TODAY (2004)
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy
CL Vogel et al.
ONCOLOGIST (2004)
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma
MA Dimopoulos et al.
HEMATOLOGY JOURNAL (2004)
Benefit and timing of second transplantations in multiple myeloma: Clinical findings and methodological limitations in a European group for blood and marrow transplantation registry study
C Morris et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34(+) cell-selected peripheral blood progenitor cell transplantation
L De Rosa et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2004)
Single versus double autologous stem-cell transplantation for multiple myeloma
M Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis
T Eriksson et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2003)
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trial
LS Rosen et al.
CANCER (2003)
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma
P Corradini et al.
BLOOD (2003)
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma
MH Kropff et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma
CK Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma.: A phase I/II study of the German Study-group Multiple Myeloma (DSMM)
N Kröger et al.
BONE MARROW TRANSPLANTATION (2003)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Partially T-Cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: A prospective evaluation of patients treated in the phase III study HOVON 24 MM
HM Lokhorst et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation
JA Pérez-Simón et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
14q32 translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinernia
H Avet-Loiseau et al.
SEMINARS IN ONCOLOGY (2003)
Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro
PAJ Haslett et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants
H Avet-Loiseau et al.
BLOOD (2003)
Serum test for assessment of patients with Bence Jones myeloma
AR Bradwell et al.
LANCET (2003)
Mobilization of CD34+ cells in elderly patients (≥ 70 years) with multiple myeloma:: influence of age, prior therapy, platelet count and mobilization regimen
CL Morris et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning
CK Lee et al.
EXPERIMENTAL HEMATOLOGY (2003)
The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma
BE Shaw et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Autologous stem cell transplantation in multiple myeloma patients < 60 vs >= 60 years of age
DE Reece et al.
BONE MARROW TRANSPLANTATION (2003)
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
DG Maloney et al.
BLOOD (2003)
Review of 1027 patients with newly diagnosed multiple myeloma
RA Kyle et al.
MAYO CLINIC PROCEEDINGS (2003)
Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality
N Kröger et al.
BLOOD (2002)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients
JR Berenson et al.
BLOOD (2002)
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma
HD Menssen et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma:: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
P Moreau et al.
BLOOD (2002)
Allogeneic transplantation for multiple myeloma:: further evidence for a GVHD-associated graft-versus-myeloma effect
R Le Blanc et al.
BONE MARROW TRANSPLANTATION (2001)
Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years
A Badros et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Results of autologous stem cell transplant in multiple myeloma patients with renal failure
A Badros et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
B Barlogie et al.
BLOOD (2001)
Thalidomide and dexamethasone combination for refractory multiple myeloma
MA Dimopoulos et al.
ANNALS OF ONCOLOGY (2001)
Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma
EV McCloskey et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma
M Drayson et al.
BLOOD (2001)
Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma:: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres
G Gahrton et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma
FE Davies et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Interferon-α treatment in multiple myeloma:: Meta-analysis of 30 randomised trials among 3948 patients
E Fritz et al.
ANNALS OF ONCOLOGY (2000)
Renal failure in multiple myeloma: reversibility and impact on the prognosis
LM Knudsen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2000)
Share Paper
